Velz J, Freudenmann L, Medici G, Dubbelaar M, Mohme M, Ghasemi D
Nat Commun. 2025; 16(1):1364.
PMID: 39904979
PMC: 11794601.
DOI: 10.1038/s41467-025-56268-0.
Fuchs K, Thomaidou S, van der Slik A, van de Meent M, t Hoen P, Falkenburg J
Mol Ther Methods Clin Dev. 2025; 33(1):101391.
PMID: 39811688
PMC: 11731205.
DOI: 10.1016/j.omtm.2024.101391.
Leddy O, Cui Y, Ahn R, Stopfer L, Choe E, Kim D
Nat Protoc. 2024; .
PMID: 39438697
DOI: 10.1038/s41596-024-01076-x.
Juanes-Velasco P, Arias-Hidalgo C, Garcia-Vaquero M, Sotolongo-Ravelo J, Paino T, Lecrevisse Q
Int J Mol Sci. 2024; 25(17).
PMID: 39273511
PMC: 11395153.
DOI: 10.3390/ijms25179564.
Ingels J, De Cock L, Stevens D, Mayer R, Thery F, Sanchez Sanchez G
Cell Rep Med. 2024; 5(5):101516.
PMID: 38626769
PMC: 11148567.
DOI: 10.1016/j.xcrm.2024.101516.
Thunder-DDA-PASEF enables high-coverage immunopeptidomics and is boosted by MSRescore with MSPIP timsTOF fragmentation prediction model.
Gomez-Zepeda D, Arnold-Schild D, Beyrle J, Declercq A, Gabriels R, Kumm E
Nat Commun. 2024; 15(1):2288.
PMID: 38480730
PMC: 10937930.
DOI: 10.1038/s41467-024-46380-y.
Enhancing Mass spectrometry-based tumor immunopeptide identification: machine learning filter leveraging HLA binding affinity, aliphatic index and retention time deviation.
Wei F, Kouro T, Nakamura Y, Ueda H, Iiizumi S, Hasegawa K
Comput Struct Biotechnol J. 2024; 23:859-869.
PMID: 38356658
PMC: 10864759.
DOI: 10.1016/j.csbj.2024.01.023.
TOF mass spectrometry-based immunopeptidomics refines tumor antigen identification.
Hoenisch Gravel N, Nelde A, Bauer J, Muhlenbruch L, Schroeder S, Neidert M
Nat Commun. 2023; 14(1):7472.
PMID: 37978195
PMC: 10656517.
DOI: 10.1038/s41467-023-42692-7.
Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery.
Zhang B, Bassani-Sternberg M
J Immunother Cancer. 2023; 11(10).
PMID: 37899131
PMC: 10619091.
DOI: 10.1136/jitc-2023-007073.
Advances in vaccine development for cancer prevention and treatment in Lynch Syndrome.
Bolivar A, Duzagac F, Sinha K, Vilar E
Mol Aspects Med. 2023; 93:101204.
PMID: 37478804
PMC: 10528439.
DOI: 10.1016/j.mam.2023.101204.
SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics.
Lim Kam Sian T, Goncalves G, Steele J, Shamekhi T, Bramberger L, Jin D
Front Immunol. 2023; 14:1107576.
PMID: 37334365
PMC: 10272402.
DOI: 10.3389/fimmu.2023.1107576.
Updated MS²PIP web server supports cutting-edge proteomics applications.
Declercq A, Bouwmeester R, Chiva C, Sabido E, Hirschler A, Carapito C
Nucleic Acids Res. 2023; 51(W1):W338-W342.
PMID: 37140039
PMC: 10320101.
DOI: 10.1093/nar/gkad335.
Immunolyser: A web-based computational pipeline for analysing and mining immunopeptidomic data.
Munday P, Fehring J, Revote J, Pandey K, Shahbazy M, Scull K
Comput Struct Biotechnol J. 2023; 21:1678-1687.
PMID: 36890882
PMC: 9988424.
DOI: 10.1016/j.csbj.2023.02.033.
Soluble HLA peptidome: A new resource for cancer biomarkers.
Tanuwidjaya E, Schittenhelm R, Faridi P
Front Oncol. 2023; 12:1069635.
PMID: 36620582
PMC: 9815702.
DOI: 10.3389/fonc.2022.1069635.
Protein evidence of unannotated ORFs in reveals diversity in the evolution and properties of young proteins.
Zheng E, Zhao L
Elife. 2022; 11.
PMID: 36178469
PMC: 9560153.
DOI: 10.7554/eLife.78772.
MSRescore: Data-Driven Rescoring Dramatically Boosts Immunopeptide Identification Rates.
Declercq A, Bouwmeester R, Hirschler A, Carapito C, Degroeve S, Martens L
Mol Cell Proteomics. 2022; 21(8):100266.
PMID: 35803561
PMC: 9411678.
DOI: 10.1016/j.mcpro.2022.100266.
The Importance of Being Presented: Target Validation by Immunopeptidomics for Epitope-Specific Immunotherapies.
Becker J, Riemer A
Front Immunol. 2022; 13:883989.
PMID: 35464395
PMC: 9018990.
DOI: 10.3389/fimmu.2022.883989.
IntroSpect: Motif-Guided Immunopeptidome Database Building Tool to Improve the Sensitivity of HLA I Binding Peptide Identification by Mass Spectrometry.
Zhang L, Liu G, Hou G, Xiang H, Zhang X, Huang Y
Biomolecules. 2022; 12(4).
PMID: 35454168
PMC: 9025654.
DOI: 10.3390/biom12040579.
Identification of tumor antigens with immunopeptidomics.
Chong C, Coukos G, Bassani-Sternberg M
Nat Biotechnol. 2021; 40(2):175-188.
PMID: 34635837
DOI: 10.1038/s41587-021-01038-8.
Is the Immunopeptidome Getting Darker?: A Commentary on the Discussion around Mishto et al., 2019.
Purcell A
Front Immunol. 2021; 12:720811.
PMID: 34326850
PMC: 8315041.
DOI: 10.3389/fimmu.2021.720811.